ObsEva Announces $20.0 Million Underwritten Offering and Concurrent Private Placement Priced At-The-Market of Common Shares and 15-Month Purchase Warrants for Potential Additional Gross Proceeds of $23.9 Million
GENEVA, Switzerland and BOSTON, MA (September 3, 2020) – ObsEva SA (NASDAQ: OBSV) (SIX: OBSN) (“ObsEva” or the “Company”), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced the pricing of an underwritten equity offering and concurrent private placement transaction.
H.C. Wainwright & Co. is acting as sole book-running manager for the underwritten offering and exclusive placement agent for the private placement.
H.C. Wainwright & Co., as underwriter, has agreed to purchase on a firm commitment basis an aggregate of 6,448,240 units at an effective price of $2.869 per unit, less underwriting discounts and commissions. Each unit is comprised of one common share (or pre-funded warrant) and one 15-month purchase warrant to purchase one common share.
"We are very pleased to add a new high quality shareholder and obtain capital to further proceed with our pipeline development as we continue ongoing active discussions for a linzagolix commercial partnership,” said Ernest Loumaye, MD, PhD, OB/GYN, CEO and Co-Founder of ObsEva.
Each 15-month purchase warrant included in the units has an exercise price of $3.43 per share, is exercisable immediately and will expire 15 months from the date of issuance. The common shares (or pre-funded warrants) and the accompanying warrants can only be purchased together in the underwritten offering but will be issued separately. The underwritten offering is expected to close on or about September 8, 2020, subject to satisfaction of customary closing conditions.
ObsEva expects to receive aggregate gross proceeds of approximately $18.5 million from the underwritten offering, prior to deducting underwriting discounts and commissions and other offering expenses. In the event the 15-month purchase warrants are exercised in full, ObsEva expects to receive approximately $22.1 million in additional gross proceeds.
The securities offered in the underwritten offering are being offered by the Company pursuant to a “shelf” registration statement on Form F-3 (File No. 333-233069) previously filed with the Securities and Exchange Commission (the “SEC”) on August 7, 2019 and declared effective by the SEC on August 14, 2019. The offering of the underwritten securities is being made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. A final prospectus supplement and accompanying prospectus relating to, and describing the terms of, the underwritten offering will be filed with the SEC and will be available on the SEC’s website at http://www.sec.gov. Electronic copies of the prospectus supplement and accompanying prospectus may also be obtained, when available, by contacting H.C. Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor, New York, NY 10022, by telephone at (646) 975-6996 or e-mail at email@example.com.
In addition to the securities being sold in the underwritten offering, the Company’s Chief Executive Officer has agreed to purchase 516,352 units, with each unit comprised of one common share and one 15-month purchase warrant to purchase one common share at an exercise price of $3.43 per share, in a concurrent private placement, exempt from the registration requirements of the Securities Act of 1933, as amended, at a purchase price equal to $2.905 per unit, for aggregate gross proceeds of approximately $1.5 million, prior to deducting placement agent fees and other placement expenses. The private placement is expected to close in the course of the month of September 2020, subject to satisfaction of customary closing conditions.
The Company intends to use the net proceeds from the offerings primarily to continue the development of the Company’s new chemical entities in its pipeline, and for working capital and other general corporate purposes.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
ObsEva is a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on treating endometriosis, uterine fibroids, preterm labor, and improving ET outcomes following IVF. ObsEva is listed on the Nasdaq Global Select Market and is trading under the ticker symbol “OBSV” and on the SIX Swiss Exchange where it is trading under the ticker symbol “OBSN”.
Cautionary Note Regarding Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “believe”, “expect”, “may”, “plan”, “potential”, “will”, and similar expressions, and are based on ObsEva’s current beliefs and expectations. These forward-looking statements include statements regarding the completion of the transactions described herein, the satisfaction of customary closing conditions related to the transactions described herein, the intended use of net proceeds from the transactions described herein. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include, without limitation, market risks and uncertainties and the satisfaction of customary closing conditions for an offering of securities and other risks and uncertainties that are described in the Risk Factors section of ObsEva’s Report on Form 6-K filed on August 6, 2020, its Annual Report on Form 20-F for the year ended December 31, 2019, and other filings ObsEva makes with the SEC. These documents are available on the Investors page of ObsEva’s website at http://www.ObsEva.com. Any forward-looking statements speak only as of the date of this press release and are based on information available to ObsEva as of the date of this release, and ObsEva assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.
For further information, please contact:
CEO Office Contact:
+41 22 552 1550
Vice President, Investor Relations
+1 857 972 9347 Office
+1 781 366 5726 Mobile
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
ZetaDisplay launches next generation global software platform25.11.2020 08:30:00 CET | Press release
Malmö - ZetaDisplay AB (publ) (Nasdaq Stockholm: ZETA) announces the launch of its next-generation software platform for proprietary, cloud-based content scheduling and distribution. The upgraded ZetaDisplay Engage will be implemented with immediate effect with the Group’s international customer base. “Despite the uncertainty in the market, we have continued to invest in our software and services offer during 2020 to accelerate growth”, says CEO Per Mandorf. “After 5,000 manhours of development we are now ready to launch the latest version of our content management system steering our customers’ Digital Signage networks”, Mandorf continues. The upgrade will happen in two phases where the initial focus will be on a state-of-the-art user interface together with a future-proof cloud-based solution. The platform offers a broad range of functionality, is easily connectable to customers’ digital ecosystem and can also handle live data. In parallel, a new standard service catalogue has been l
ZetaDisplay lanserar nästa generations globala mjukvaruplattform25.11.2020 08:30:00 CET | Pressemelding
Malmö - ZetaDisplay AB (publ) (Nasdaq Stockholm: ZETA) lanserar sin egenutvecklade nästa generations mjukvaruplattform för schemaläggning och distribution av molnbaserat innehåll. Den uppgraderade mjukvaran ZetaDisplay Engage kommer att implementeras med omedelbar verkan hos koncernens internationella kundbas. "Trots osäkerheten på marknaden har vi fortsatt att investera i vårt mjukvaru- och tjänsteerbjudande under 2020 för att accelerera tillväxten", säger VD Per Mandorf. " Efter 5 000 mantimmar av utveckling är vi nu redo att lansera den senaste versionen av vårt content management system som styr våra kunders Digital Signage-installationer", fortsätter Mandorf. Uppgraderingen kommer att ske i två faser där det inledande fokuset kommer att ligga på ett toppmodernt användargränssnitt tillsammans med en framtidssäker molnbaserad lösning. Plattformen erbjuder ett brett utbud av funktionalitet, är lätt att ansluta till kundernas digitala ekosystem och kan även hantera livedata. Parallell
ArcAroma AB: 201125 Samarbetsavtal med OptiFreeze ökar möjligheten till accelerad tillväxt25.11.2020 08:30:00 CET | Pressemelding
Pressmeddelande 2020-11-25 ArcAroma och OptiFreeze har idag tecknat ett utvärderingsavtal gällande samarbete. Syftet med avtalet är att utvärdera möjligheten till framtida gemensamma projekt för livsmedelsapplikationer. ArcAromas organisation kommer dessutom stödja OptiFreeze i deras marknadsexpansion för snittblommor. ArcAroma har under de senaste åren mer och mer fokuserat på livsmedelssektorn. Bolaget ser en stor potential i denna globala marknad och har olika applikationer under marknadsutveckling och nya i utvecklingsfas. ArcAromas ledning och styrelse ser att ett fördjupat samarbete med OptiFreeze erbjuder en stor potential att skapa ett starkare och konkurrenskraftigare ArcAroma inom livsmedelsteknik. Det tekniska och vetenskapliga kunnandet i respektive bolag är komplementära. ArcAroma har redan ett starkt fokus på olika livsmedel och här skulle OptiFreeze gedigna grundforskning och höga kompetens inom metodutveckling kunna bidra till att bredda applikationsportföljen. ArcAroma
Avance Gas Holding Ltd Reports Unaudited Results for the Third Quarter of 202025.11.2020 08:00:00 CET | Press release
BERMUDA, 25 November 2020 – Avance Gas Holding Ltd (OSE: AVANCE) today reported unaudited results for the third quarter 2020. HIGHLIGHTS An achieved time charter equivalent (TCE) rate of $23,283 on a discharge to discharge basis and $21,524/day on the basis of IFRS 15 accounting standard, compared to $28,453/day and $28,932/day in Q2 2020 respectively.The TCE rates in Q3 reflects ballast cost of approx. $4,000/day, corresponding to an adjusted TCE rate of $27,283 in Q3. The ballast cost will recover into the following quarter.Daily operating expenses (OPEX) were $9,256/day, compared to $8,576/day in Q2 2020. OPEX was impacted by change of technical manager and Covid-19 related crew change expense representing approx. $900/day in Q3.A&G expenses were $727/day, up from $608/day in Q2.Secured funding for predelivery CAPEX of newbuilding program through two transactions In September, the sale of the 2003-built VLGC Avance was successfully completed. Following repayment of debt, the transac
Incap Corporation: Incap Group’s Business Review for January–September 2020: Back on track with good growth and profitability25.11.2020 07:30:00 CET | Press release
Incap Corporation Stock Exchange Release Business Review Q3 2020 25 November 2020 at 8.30 a.m. (EET) Incap Group’s Business Review for January–September 2020: Back on track with good growth and profitability July–September 2020 highlights The revenue of the third quarter amounted to EUR 28.1 million, showing an increase of 59.9% (7– 9/2019: EUR 17.6 million).Excluding revenue from AWS Electronics Group acquired in January 2020, the revenue increased organically by 10.7%.Adjusted EBIT was EUR 3.6 million (EUR 2.4 million), corresponding to 12.9% of revenue (13.7%).AWS Electronics Group acquisition related purchase price allocation (PPA) amortisation amounted to EUR 0.4 million (EUR 0.0 million) and non-recurring costs were EUR 0.0 million (EUR 0.2 million). Operating profit (EBIT) was EUR 3.3 million (EUR 2.2 million), an increase of 46.0%, corresponding to 11.6% of revenue (12.7%).Net profit for the period was EUR 2.4 million (EUR 1.8 million), an increase of 33.7%.In November 2020, In
FRO - Third Quarter and Nine Months 2020 Results25.11.2020 07:29:39 CET | Press release
Frontline Ltd. (the “Company” or “Frontline”), today reported unaudited results for the three and nine months ended September 30, 2020: Highlights Net income of $57.1 million, or $0.29 per diluted share for the third quarter of 2020 Adjusted net income of $56.4 million, or $0.29 per diluted share for the third quarter of 2020Reported total operating revenues of $247.4 million for the third quarter of 2020Reported spot TCEs for VLCCs, Suezmax tankers and LR2 tankers in the third quarter of 2020 were $49,200, $25,100 and $12,800 per day, respectivelyFor the fourth quarter of 2020, we estimate spot TCE on a load-to discharge basis of $22,600 contracted for 74% of vessel days for VLCCs, $12,600 contracted for 61% of vessel days for Suezmax tankers and $13,800 contracted for 65% of vessel days for LR2 tankers. We expect the spot TCEs for the full fourth quarter of 2020 to be lower than the TCEs currently contracted, due to the impact of ballast days at the end of the fourth quarter as well